

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Katsuo SUEISHI et al.	Confirmation No.:	2391
Serial No.:	10/598,947	Art Unit:	1646
371 (c) Date:	March 27, 2007	Examiner:	Prema Maria Mertz
Customer No.:	21559		
Title:	METHODS FOR SUPPRESSING TUMOR PROLIFERATION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was sent in connection with the above-captioned case on March 27, 2009, Applicants elect the invention of Group VII (claims 9, 10, 11, 13, and 17, as directed to an antitumor agent where the antitumor agent is a minus strand RNA virus vector encoding a secretory protein), and the species of (c) adenocarcinoma. The election is made without traverse. Claims 9, 10, 11, 13, and 17 read on the elected species.

Applicants note that, while claim 9 recites “a compound that inhibits the expression of a PDGF-A or the binding between a PDGF-A homodimer and a PDGFR α as an active ingredient,” the Office’s description of Groups IV-VII, which include claim 9, only recites “an antitumor agent that inhibits the expression of a PDGF-A” and does not recite inhibiting “binding between a PDGF-A homodimer and a PDGFR α .”

Applicants note that a minus strand RNA virus vector encoding a secretory protein, as elected in Group VII, may be used to inhibit binding between a PDGF-A homodimer and a PDGFR α . Applicants wish to clarify that the elected invention should not be limited to an antitumor agent that inhibits expression of a PDGF-A.


Transmitted herewith is a Petition to extend the period for replying to the Restriction Requirement for two (2) months, to and including June 27, 2009, and payment of the required extension fee.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

9 June 2009



Jan N. Tittel, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045